BACKGROUND: S-1 is a novel oral fluorouracil prodrug active against non-small cell lung cancer (NSCLC). To determine the feasibility of S-1 combined with weekly irinotecan for patients with advanced NSCLC, we performed a phase I study to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of irinotecan. METHODS: Patients with advanced NSCLC received S-1 (80 mg/m(2)) on days 1-14 and irinotecan (50-80 mg/m(2)) on days 1, 8, and 15 of each 28-day cycle. Three to six patients were treated with each dose of irinotecan, with the MTD defined as the dose at which dose-limiting toxicity (DLT) appeared in 33% of patients. RESULTS: At doses of 50-70 mg/m(2), no patients experienced any DLT, whereas, at a dose of 80 mg/m(2), two of four patients experienced DLTs. Two patients experienced grade 3 toxicities - neutropenia and diarrhea. CONCLUSION: The MTD of weekly irinotecan was 80 mg/m(2), making its RD for phase II trials 70 mg/m(2).
BACKGROUND: S-1 is a novel oral fluorouracil prodrug active against non-small cell lung cancer (NSCLC). To determine the feasibility of S-1 combined with weekly irinotecan for patients with advanced NSCLC, we performed a phase I study to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of irinotecan. METHODS:Patients with advanced NSCLC received S-1 (80 mg/m(2)) on days 1-14 and irinotecan (50-80 mg/m(2)) on days 1, 8, and 15 of each 28-day cycle. Three to six patients were treated with each dose of irinotecan, with the MTD defined as the dose at which dose-limiting toxicity (DLT) appeared in 33% of patients. RESULTS: At doses of 50-70 mg/m(2), no patients experienced any DLT, whereas, at a dose of 80 mg/m(2), two of four patients experienced DLTs. Two patients experienced grade 3 toxicities - neutropenia and diarrhea. CONCLUSION: The MTD of weekly irinotecan was 80 mg/m(2), making its RD for phase II trials 70 mg/m(2).
Authors: V Georgoulias; E Papadakis; A Alexopoulos; X Tsiafaki; A Rapti; M Veslemes; P Palamidas; I Vlachonikolis Journal: Lancet Date: 2001-05-12 Impact factor: 79.321
Authors: T Shirasaka; Y Shimamato; H Ohshimo; M Yamaguchi; T Kato; K Yonekura; M Fukushima Journal: Anticancer Drugs Date: 1996-07 Impact factor: 2.248
Authors: Y Ohe; Y Ohashi; K Kubota; T Tamura; K Nakagawa; S Negoro; Y Nishiwaki; N Saijo; Y Ariyoshi; M Fukuoka Journal: Ann Oncol Date: 2006-11-01 Impact factor: 32.976
Authors: Egbert F Smit; Jan P A M van Meerbeeck; Pilar Lianes; Channa Debruyne; Catherine Legrand; Franz Schramel; Hans Smit; Rabab Gaafar; Bonne Biesma; Chris Manegold; Niels Neymark; Giuseppe Giaccone Journal: J Clin Oncol Date: 2003-11-01 Impact factor: 44.544
Authors: M Inokuchi; T Yamashita; H Yamada; K Kojima; W Ichikawa; Z Nihei; T Kawano; K Sugihara Journal: Br J Cancer Date: 2006-04-24 Impact factor: 7.640
Authors: S Negoro; N Masuda; Y Takada; T Sugiura; S Kudoh; N Katakami; Y Ariyoshi; Y Ohashi; H Niitani; M Fukuoka Journal: Br J Cancer Date: 2003-02-10 Impact factor: 7.640